Healey & AMG Center Announces Update in ALS Platform Trial with Trehalose
The Healey & AMG Center has announced the latest updates regarding Regimen E of the HEALEY ALS Platform Trial evaluating Trehalose.
Contact Information
Dr. Babu is an Assistant Professor of Neurology at Harvard Medical School and serves as neuromuscular faculty. She provides clinical care for people with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases at the multidisciplinary ALS clinic at the Healey Center for ALS. In addition, she provides clinical care for people with neuromuscular disorders at the Mass General Neuromuscular Division.
Dr. Babu completed her Neurology training at the Cleveland Clinic, Ohio and two fellowships in Neuromuscular diseases and Neurodegenerative disorders at Harvard Medical School. She has completed a 2-year competitive Clinical and Translational Research Academy program at Harvard Medical School.
Dr. Babu serves as a physician investigator in ALS. She has a special interest in developing disease modifying treatments and clinical trial biomarker readouts for people with ALS and motor neuron diseases. Her clinical research work is primarily aimed at improving ALS patient care and survival outcomes. Her research work focuses on characterizing and quantifying neuroinflammation and other disease mechanism markers of disease progression in individuals with various forms of ALS, using advanced neuroimaging techniques, such as MRI and PET imaging along with markers in blood and spinal fluid and clinical outcome measures. She has led as the overall Principal Investigator for two multi-site clinical research studies using novel PET imaging readouts. She leads several Phase 1, 2 and 3 clinical trials evaluating novel therapeutics for sporadic and familial ALS as the site Principal Investigator for Mass General.
Dr. Babu collaborates with ALS researchers across the world and has published several high impact scientific publications. She co-chairs the NEALS Consortium imaging subcommittee, an international organization for ALS researchers. Her research is funded by prestigious awards from American Academy of Neurology, ALS Association and Muscular Dystrophy Association.
Clinical Interests:
Treats:
Languages:
Sean M. Healey and AMG Center for ALS
55 Fruit Street
Wang Ambulatory Care Center
8th Floor
Boston, MA 02114
Phone: 617-724-3914
Mass General Neurology: Neuromuscular
165 Cambridge St.
Charles River Plaza
Suite 820
Boston, MA 02114
Phone: 617-726-3642
Mass General Neurology: Neurological Clinical Research Institute
165 Cambridge St.
6th Floor
Boston, MA 02114
Phone: 617-726-5732
Medical Education
American Board Certifications
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Secure online access to your health information whenever you need it. Check appointments, communicate with your provider and pay bills online 24/7.
Mass General is recognized as a top hospital on the U.S. News Best Hospitals Honor Roll for 2024-2025.
The Healey & AMG Center has announced the latest updates regarding Regimen E of the HEALEY ALS Platform Trial evaluating Trehalose.
DNL343 is a novel investigational ALS therapy that targets eIF2B, a central regulator of the integrated stress response (ISR).
The grant is supported by the ACT for ALS (Accelerating Access to Critical Therapies for ALS Act), and this study is the very first EAP made possible by the bill.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Northeast ALS (NEALS) Consortium announced results from Regimen D of the HEALEY ALS Platform Trial evaluating pridopidine versus placebo in adults with amyotrophic lateral sclerosis (ALS).
The HEALEY ALS Platform Trial led by the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital (MGH) today announced topline results from Regimen C evaluating CMN-Au8, developed by Clene Nanomedicine, Inc.